Baetge, Sharon Jean
Filser, Melanie
Renner, Alina
Raithel, Lina Marie
Lau, Stephanie
Pöttgen, Jana
Penner, Iris-Katharina http://orcid.org/0000-0002-6746-1034
Funding for this research was provided by:
German MS society
Novartis Pharma
University of Bern
Article History
Received: 10 November 2022
Revised: 8 February 2023
Accepted: 8 February 2023
First Online: 25 February 2023
Declarations
:
: S.J. Baetge has no relevant financial or non-financial interests to disclose. M. Filser has no relevant financial or non-financial interests to disclose. A. Renner has no relevant financial or non-financial interests to disclose. L.M. Raithel has no relevant financial or non-financial interests to disclose. S. Lau reports has no relevant financial or non-financial interests to disclose. J. Pöttgen has no relevant financial or non-financial interests to disclose. I.K. Penner reports to have received honoraria for speaking at scientific meetings, serving at scientific advisory boards and consulting activities from Adamas Pharma, Almirall, Bayer Pharma, Biogen, BMS, Celgene, Genzyme, Janssen, Merck, Novartis, Roche, and Teva. She received research support from the German MS Society, Celgene, Novartis, Roche, and Teva. All payments were transferred to the institution.